Fintel reports that on January 30, 2025, Stifel upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Hold to Buy.

Edwards Lifesciences Corporation (NYSE:EW) shares are trading higher on Thursday. Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests ...

In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW, showcasing a mix of bullish and bearish ...

Shares of Edwards Lifesciences Corp. EW advanced 2.94% to $73.22 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.53% to ...

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

Stifel analysts upgraded Edwards Lifesciences (NYSE:EW) stock from Hold to Buy, citing potential growth acceleration in the Transcatheter Aortic Valve Replacement (TAVR) market. The firm also ...

New 20-year data show a survival rate of 90% with few repeat surgeries after this complex operation that can only be ...

Jefferies analyst Kaumil Gajrawala upgraded the rating for The Coca-Cola Company KO from Hold to Buy and increased the price target from $69 to $75. Coca-Cola shares closed at $62.83 on Wednesday. See ...